van Brummelen, Emilie M J <br/><br/>
A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma.  [electronic resource] 

 -  Investigational new drugs  04 2020 
 - 457-467 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1573-0646 
<br/><br/><label>Standard No.: </label>10.1007/s10637-019-00783-7  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Cisplatin--administration & dosage<br/>Female<br/>Fibroblast Growth Factor 2--metabolism<br/>Humans<br/>Immunoglobulin G--administration & dosage<br/>Ligands<br/>Male<br/>Mesothelioma, Malignant--drug therapy<br/>Middle Aged<br/>Oncogene Proteins, Fusion--administration & dosage<br/>Pemetrexed--administration & dosage<br/>Receptor, Fibroblast Growth Factor, Type 1--administration & dosage<br/>Recombinant Fusion Proteins<br/>Treatment Outcome